PharmaJet has entered a global license agreement with Genexine for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.    Under the terms of the agreement, Genexine will use both the PharmaJet Stratis® and Tropis® devices in their Phase 1 and IIa human clinical studies. The agreement also includes provision for potential expansion to include Phase III studies and commercialization.   “We are pleased...